Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
about
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Management of adverse events related to checkpoint inhibition therapy.
P2860
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Possible adverse effects of im ...... t and follow-up of three cases
@en
type
label
Possible adverse effects of im ...... t and follow-up of three cases
@en
prefLabel
Possible adverse effects of im ...... t and follow-up of three cases
@en
P2093
P2860
P50
P1476
Possible adverse effects of im ...... t and follow-up of three cases
@en
P2093
Anastasia Athanasiadou
Anastasios Kallianos
Dimitris Hatzibougias
Eirini Goupou
Electra Mihalopoulou
Haidong Huang
Lemonia Veletza
Panos Chinelis
Paul Zarogoulidis
Theodora Tsiouda
P2860
P304
P356
10.1016/J.RMCR.2017.07.004
P577
2017-07-14T00:00:00Z